Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a Buy now.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...